fda compounding semaglutide warning letters october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The FDA has received reports

Injectable GHK-Cu should only be handled by a licensed medical professional

And not in a trendy, flash in the pan way

Patient safety considerations : If you experience worsening neurological symptoms or develop new symptoms despite treatment, contact your GP promptly

Gala GLP-1 is a telehealth platform that connects patients with licensed healthcare providers who evaluate medical eligibility for prescription weight management treatment

Los efectos percibidos pueden variar entre individuos

Nomura S, Katoh H, Yanagisawa S, Noguchi T, Okada K, Watanabe M (2023) Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress